Author

Peter L Lakatos 1

1 Semmelweis University Faculty of Medicine 1st Dept. of Medicine - 1st Department of Medicine, Semmelweis University Faculty of Medicine 1st Dept. of Medicine; Budapest/HU

3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 2: Surgical Management and Special Situations

Paolo Gionchetti, Axel Dignass, Sllvio Danese, Fernando Jose Magro Dias, Gerhard Rogler, Peter L Lakatos, Michel Adamina, Alessandro Ardizzone, Christianne Johanna Buskens, Shaji Sebastian, Silvio Laureti, Gianluca M Sampietro, Boris Vucelic, C. Janneke van der Woude, Manuel Barreiro de Acosta, Christian Maaser, Francisco P

ARE EXTRAINTESTINAL MANIFESTATIONS ASSOCIATED WITH DISEASE OUTCOMES IN INFLAMMATORY BOWEL DISEASES? RESULTS FROM THE VESZPREM POPULATION BASED INCEPTION COHORT DATABASE

Petra Anna Golovics, Barbara Dorottya Lovasz, Zsuzsanna Vegh, Istvan Szita, Mihaly Balogh, Stephan Vavricka, Gerhard Rogler, Peter L Lakatos, Peter L Lakatos

BENEFITS OF IMPLEMENTING A RAPID ACCESS CLINIC IN A HIGH VOLUME INFLAMMATORY BOWEL DISEASE CENTER: ACCESS, RESOURCE UTILIZATION AND OUTCOMES

Sofia Nene, Zsuzsanna Kürti, Isabelle Morin, Talat Bessissow, Waqqas Afif, Gary Wild, Ernest Seidman, Alain Bitton, Peter L Lakatos

Benefits of implementing a rapid access clinic in a high volume inflammatory bowel disease center: access, resource utilization and outcomes

Sofia Nene, Lorant Gonczi, Christine Verdon, Jason Reinglas, Rita Kohen, Talat Bessissow, Waqqas Afif, Gary Wild, Ernest Seidman, Alain Bitton, Peter L Lakatos

BIOSIMILAR INFLIXIMAB: EFFICACY AND SAFETY BASED ON INTERIM RESULTS FROM A PROSPECTIVE NATIONWIDE COHORT

Krisztina Barbara Gecse, Klaudia Farkas, Barbara Dorottya Lovasz, János Banai, László Bene, Beata Gasztonyi, Petra Anna Golovics, Tünde Kristóf, Peter L Lakatos, Pal Miheller, Ferenc Nagy, Karoly Palatka, Mária Papp, Árpád V. Patai, Ágnes Szabone Salamon, Tamás Szamosi, Zoltan Gabor Szepes, Gábor Tamás Tóth, Aron Vincze;;

CHANGES IN THERAPEUTIC STRATEGY AND OUTCOMES IN NEWLY DIAGNOSED PATIENT WITH CROHN’S DISEASE IN THE BIOLOGICAL ERA IN HUNGARY: A NATIONWIDE STUDY BASED ON THE NATIONAL HEALTH INSURANCE FUND DATABASE

Zsuzsanna Kürti, Lorant Gonczi, Zsuzsanna Vegh, Petra Anna Golovics, Petra Fadgyas-Freyler, Judit Gimesi-Országh, Gyula Korponai, Barbara Dorottya Lovasz, Krisztina Barbara Gecse, Peter L Lakatos

CLINICAL EFFICACY, DRUG SUSTAINABILITY AND RESULTS FROM THERAPEUTIC DRUG MONITORING IN CROHN'S DISEASE PATIENTS TREATED WITH USTEKINUMAB - 1-YEAR FOLLOW-UP OF A PROSPECTIVE, NATIONWIDE, MULTICENTER COHORT FROM HUNGARY

Lorant Gonczi, Kata Szántó, Klaudia Farkas, Tamás Molnár, Tamás Szamosi, Eszter Schäfer, Petra Anna Golovics, Barbara Dorottya Lovasz, Mark Juhasz, Árpád V. Patai, Aron Vincze, Patrícia Sarlós, Karoly Palatka, Alexandra Farkas, Gábor Tamás Tóth, Peter L Lakatos, Pal Miheller, Ákos Iliás

Combination therapy: Con

Peter L Lakatos

COST-UTILITY OF BIOSIMILAR INFLIXIMAB (INFLECTRA©) FOR THE TREATMENT OF LUMINAL CROHN?S DISEASE IN NINE EUROPEAN COUNTRIES

Fanni Rencz, Valentin Brodszky, Petra Baji, Marta Pentek, Laszlo Gulacsi, Petra Anna Golovics, Zsuzsanna Vegh, Krisztina Barbara Gecse, Silvio Danese, Peter Irving, Peter L Lakatos

COST-UTILITY OF BIOSIMILAR INFLIXIMAB FOR THE TREATMENT OF FISTULISING CROHN?S DISEASE IN NINE EUROPEAN COUNTRIES

Petra Baji, Marta Pentek, Valentin Brodszky, Laszlo Gulacsi, Fanni Rencz, Petra Anna Golovics, Krisztina Barbara Gecse, Zsuzsanna Vegh, Silvio Danese, Peter Irving, Peter L Lakatos

Item 1 - 10 / 131
1
2 3 4 5 6 7
...
13 14